An acquirer is looking to buy/acquire major stake in a profitable company in the healthcare, ITES and Telecom VAS segment.
The company should be service oriented company with asset light business model with turnover of up to Rs. 40 Cr.
The company/business should have successfully crossed the proof of concept stage and should have steady revenue stream.
It should be profitable business with a robust business pipeline, primarily targeting mass market (not to any niche market segment).
The present management should be available to stay on at the choice of the buyer. However, the management control would invariably have to be with the buyer. They would look to acquire minimum 51% stake. While a majority stake/outright purchase is the preferred route, the client is open to considering JVs and buying minority stake as well (but with Affirmative rights).
Scalability of operations with the support of the buyer is an important criterion.
Preferably, it should be headquartered in North India/NCR
To shore up more Foreign Investments, the government liberalized FDI limits in dozen sectors to boost the sagging economy. Stock markets reacted positively after the government relaxed FDI norms in several sectors.
The clinical-stage specialty bio-pharmaceutical company Vyome Biosciences Private Limited has raises $14 million in Series-C financing round. The financing round was led by a prominent New York based life sciences fund Perceptive Advisors. Apart from that the funding round saw participation of a Boston-based venture capital Romulus Capital along with existing investors.